安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home | Harrow, Inc.
Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
- Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary . . .
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Integration into Harrow: Melt Pharmaceuticals will be fully integrated into Harrow’s operations to ensure a seamless transition and accelerate progress toward NDA submission, approval, and market launch
- Harrow Announces Third Quarter 2025 Financial Results
In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full range of branded, generic, and compounded ophthalmic medications
- Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where initiative is celebrated, creativity thrives, and impact is real
- 0001493152-25-023988 | 8-K | Harrow, Inc.
Document Details Form 8-K Filing Date November 18, 2025 Document Date November 17, 2025 Form Description Report of unscheduled material events or corporate event Filing Group Current Reports Company Harrow, Inc Issuer
- Form 8-K for Harrow INC filed 10 06 2025
Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes For more information about Harrow, please visit harrow com
- Investor Analyst Day - harrow. com
Harrow has entered into an agreement with a drug delivery company founded by Mark Humayun, MD, PhD (USC) and YC Tai, PhD (CalTech), securing the option to acquire full U S rights to the product, pending the outcome of in-process clinical study
|
|
|